Skip to main content
Smart Investors Daily
CZ

OTC · CZMWY

Carl Zeiss Meditec AG

Healthcare · Medical - Instruments & Supplies

$40.21

Up+$1.07 (+2.72%)

Updated Nov 5, 2026, 12:44 PM

SID Score

5.2/10

Composite research score

Smart Money

46/100

Neutral

Market cap
4.13B
P/E ratio
23.5
Dividend yield
1.55%
52-week range
— – —
Volume
400
Avg. volume
2.42K

Price performance · CZMWY

CZMWY price history

1M range · 0 trading sessions · Daily adjusted prices

CZMWY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CZMWY news

The latest Smart Investors Daily articles mentioning CZMWY.

CZMWY research

Overview

Company profile and research snapshot.

Company profile

CARL ZEISS MEDI UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CZMWY recent ratings
DateFirmRatingTarget
Sep 21, 2026BERENBERGHold—
Aug 28, 2026METZLER EQUITIESBuy—
Aug 26, 2026LANDESBANK BADEN-WUERTTEMBERGHold—
Aug 14, 2026EQUITA SIMHold—
Aug 14, 2026DZ BANKHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow

ZEISS Medical Technology announced today the commercial availability of the CT LUCIA® 621P monofocal IOL from ZEISS in Japan, expanding the ZEISS Cataract Workflow in the Japanese market to support good visual outcomes. The ZEISS CT LUCIA 621P will be showcased at the 80th Annual Congress of Japan Clinical Ophthalmology (JCO) in Kyoto, Japan, from Oct. 29 – Nov. 1, 2026.

Yahoo · Oct 22, 2026

Carl Zeiss Meditec (XTRA:AFX) Stock Still Looks Below Fair Value After 79% Fall

Carl Zeiss Meditec has seen its share price move sharply over recent years, and the question now is whether the current €34.22 level lines up with what its earnings actually justify. For anyone eyeing the stock after a recent rebound, the key issue is how that price squares with the profits the business is generating today. Over the past 5 years the share price has fallen 78.9%, which puts the focus squarely on whether the earnings multiple now attached to Carl Zeiss Meditec still makes...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.